The cystine transporter (system xC-) is an antiporter of cystine and glutamate. It has relatively low basal expression in most tissues and becomes upregulated in cells under oxidative stress (OS) as one of the genes expressed in response to the antioxidant response element promoter. We have developed 18F-5-fluoroaminosuberic acid (FASu), a PET tracer that targets system xC- The goal of this study was to evaluate 18F-FASu as a specific gauge for system xC- activity in vivo and its potential for breast cancer imaging. Methods: 18F-FASu specificity toward system xC- was studied by cell inhibition assay, cellular uptake after OS induction with diethyl maleate, with and without anti-xCT small interfering RNA knockdown, in vitro uptake studies, and in vivo uptake in a system xC--transduced xenograft model. In addition, radiotracer uptake was evaluated in 3 breast cancer models: MDA-MB-231, MCF-7, and ZR-75-1. Results: Reactive oxygen species-inducing diethyl maleate increased glutathione levels and 18F-FASu uptake, whereas gene knockdown with anti-xCT small interfering RNA led to decreased tracer uptake. 18F-FASu uptake was robustly inhibited by system xC- inhibitors or substrates, whereas uptake was significantly higher in transduced cells and tumors expressing xCT than in wild-type HEK293T cells and tumors (P < 0.0001 for cells, P = 0.0086 for tumors). 18F-FASu demonstrated tumor uptake in all 3 breast cancer cell lines studied. Among them, triple-negative breast cancer MDA-MB-231, which has the highest xCT messenger RNA level, had the highest tracer uptake (P = 0.0058 when compared with MCF-7; P < 0.0001 when compared with ZR-75-1). Conclusion: 18F-FASu as a system xC- substrate is a specific PET tracer for functional monitoring of system xC- and OS imaging. By enabling noninvasive analysis of xC- responses in vivo, this biomarker may serve as a valuable target for the diagnosis and treatment monitoring of certain breast cancers.
The cystine transporter (system xC-) is an antiporter of cystine and glutamate. It has relatively low basal expression in most tissues and becomes upregulated in cells under oxidative stress (OS) as one of the genes expressed in response to the antioxidant response element promoter. We have developed 18F-5-fluoroaminosuberic acid (FASu), a PET tracer that targets system xC- The goal of this study was to evaluate 18F-FASu as a specific gauge for system xC- activity in vivo and its potential for breast cancer imaging. Methods:18F-FASu specificity toward system xC- was studied by cell inhibition assay, cellular uptake after OS induction with diethyl maleate, with and without anti-xCT small interfering RNA knockdown, in vitro uptake studies, and in vivo uptake in a system xC--transduced xenograft model. In addition, radiotracer uptake was evaluated in 3 breast cancer models: MDA-MB-231, MCF-7, and ZR-75-1. Results:Reactive oxygen species-inducing diethyl maleate increased glutathione levels and 18F-FASu uptake, whereas gene knockdown with anti-xCT small interfering RNA led to decreased tracer uptake. 18F-FASu uptake was robustly inhibited by system xC- inhibitors or substrates, whereas uptake was significantly higher in transduced cells and tumors expressing xCT than in wild-type HEK293T cells and tumors (P < 0.0001 for cells, P = 0.0086 for tumors). 18F-FASu demonstrated tumor uptake in all 3 breast cancer cell lines studied. Among them, triple-negative breast cancerMDA-MB-231, which has the highest xCT messenger RNA level, had the highest tracer uptake (P = 0.0058 when compared with MCF-7; P < 0.0001 when compared with ZR-75-1). Conclusion:18F-FASu as a system xC- substrate is a specific PET tracer for functional monitoring of system xC- and OS imaging. By enabling noninvasive analysis of xC- responses in vivo, this biomarker may serve as a valuable target for the diagnosis and treatment monitoring of certain breast cancers.
Authors: Susanne Müerköster; Alexander Arlt; Maike Witt; André Gehrz; Sieglinde Haye; Christina March; Frauke Grohmann; Kai Wegehenkel; Holger Kalthoff; Ulrich R Fölsch; Heiner Schäfer Journal: Int J Cancer Date: 2003-04-20 Impact factor: 7.396
Authors: Jack M Webster; Christine A Morton; Bruce F Johnson; Hua Yang; Michael J Rishel; Brian D Lee; Qing Miao; Chittari Pabba; Donald T Yapp; Paul Schaffer Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057
Authors: Patrick N McCormick; Hannah E Greenwood; Matthias Glaser; Oliver D K Maddocks; Thibault Gendron; Kerstin Sander; Gayatri Gowrishankar; Aileen Hoehne; Tong Zhang; Adam J Shuhendler; David Y Lewis; Mathias Berndt; Norman Koglin; Mark F Lythgoe; Sanjiv S Gambhir; Erik Årstad; Timothy H Witney Journal: Cancer Res Date: 2018-11-06 Impact factor: 12.701
Authors: Catherine Hou; Chia-Ju Hsieh; Shihong Li; Hsiaoju Lee; Thomas J Graham; Kuiying Xu; Chi-Chang Weng; Robert K Doot; Wenhua Chu; Subhasish K Chakraborty; Laura L Dugan; Mark A Mintun; Robert H Mach Journal: ACS Chem Neurosci Date: 2017-12-03 Impact factor: 4.418
Authors: Jonathan K M Lim; Alberto Delaidelli; Sean W Minaker; Hai-Feng Zhang; Milena Colovic; Hua Yang; Gian Luca Negri; Silvia von Karstedt; William W Lockwood; Paul Schaffer; Gabriel Leprivier; Poul H Sorensen Journal: Proc Natl Acad Sci U S A Date: 2019-04-18 Impact factor: 11.205
Authors: Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse Journal: Oncotarget Date: 2017-12-07